Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8432
−$0.0133 · -1.55%
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Previous close
$0.8432
−$0.0133 · -1.55%
Regular session · ET · Market data may be delayed.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Day range
Current $0.8432
52-week range
Current $0.8432
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Sentiment
56
Mixed
Risk
65
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Day range
Current $0.8432
52-week range
Current $0.8432
Operating income
Net income
| Metric (CAD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 13.31M CAD | 15.44M CAD | 13.35M CAD | 11.37M CAD | 12.92M CAD |
| Selling, general, and administrative | 15.41M CAD | 10.1M CAD | 11.82M CAD | 8.18M CAD | 12.86M CAD |
| Operating expenses | 28.73M CAD | 25.54M CAD | 25.47M CAD | 19.84M CAD | 26.23M CAD |
| Interest income | 529.64K CAD | 1.2M CAD | 1.33M CAD | 528K CAD | — |
| Depreciation and amortization | 70K CAD | 87K CAD | 303.78K CAD | 288.83K CAD | 452K CAD |
| Operating income | −28.73M CAD | −25.54M CAD | −25.47M CAD | −19.84M CAD | −26.23M CAD |
| Net income | −28.76M CAD | −22.79M CAD | −20.92M CAD | −18.3M CAD | −26.3M CAD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 25, 2018 | 2:19 | — | — |
Effective May 25, 2018
2:19
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
